<SEC-DOCUMENT>0001019056-19-000520.txt : 20191120
<SEC-HEADER>0001019056-19-000520.hdr.sgml : 20191120
<ACCEPTANCE-DATETIME>20190909172547
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001019056-19-000520
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		800 WEST VALLEY PARKWAY
		STREET 2:		SUITE 203
		CITY:			ESCONDIDO
		STATE:			CA
		ZIP:			92025
		BUSINESS PHONE:		949-370-9062

	MAIL ADDRESS:	
		STREET 1:		800 WEST VALLEY PARKWAY
		STREET 2:		SUITE 203
		CITY:			ESCONDIDO
		STATE:			CA
		ZIP:			92025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="width: 35"><FONT STYLE="font-size: 10pt">September 9, 2019</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>VIA EDGAR</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Securities and
Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Division of
Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">100 F Street,
N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Attn: Thomas Jones</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.3pt; text-align: justify; text-indent: -94.3pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                      <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47pt"><FONT STYLE="font-size: 10pt">Re:</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Modular
                                         Medical, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Registration
                                         Statement on Form S-1</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 94.3pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Filed
                                         on June 27, 2019</FONT></TD></TR>                                                                          <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>File
                                         No. 333-232377&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 94.5pt; text-align: justify; text-indent: -94.5pt"><FONT STYLE="font-size: 10pt">Dear
Mr. Jones:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Modular
Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;) hereby submits this letter in response to comments from the staff (the &ldquo;<U>Staff</U>&rdquo;)
of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) set forth in its letter dated July 23, 2019 (the
&ldquo;<U>Comment Letter</U>&rdquo;) relating to the above-referenced Registration Statement on Form S-1 (the &ldquo;<U>Registration
Statement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Set
forth below in bold are the Staff&rsquo;s comments from the Comment Letter. For your convenience, each of the numbered paragraphs
below corresponds to the numbered comment in the Comment Letter and includes the caption used in the Comment Letter. Immediately
following each comment is the Company&rsquo;s response to that comment. Defined terms used but not otherwise defined herein have
the meanings ascribed to such terms in the Registration Statement.</FONT><FONT STYLE="font-size: 10pt">&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 205.65pt 12pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Cover
Page</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.75pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.25pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
                                         disclose the fixed price at which the securities will be sold in this offering. See Item
                                         501(b)(3) of Regulation S-K. Depending on your responses to the other comments in this
                                         letter, you may disclose, if true, that the selling shareholders will sell at the disclosed
                                         fixed price per share until your shares are quoted on the OTC Bulletin Board or in the
                                         OTCQX or OTCQB marketplace of OTC Link and thereafter at prevailing market prices or
                                         at privately negotiated prices.</B></FONT><B><FONT STYLE="font-family: Symbol; font-size: 10pt"><SUP>*
                                         </SUP></FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
                                         also make corresponding changes elsewhere in the prospectus.</FONT></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s comment, we have made the requested change on the Prospectus cover page and Plan of Distribution
section of the Prospectus and have added the following risk factor which incorporates such disclosure in the &ldquo;Risk Factor&rdquo;
section of the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Symbol"><SUP>*</SUP></FONT><FONT STYLE="font-size: 10pt">
<FONT STYLE="font-family: Times New Roman, Times, Serif">As requested by the Staff the last 4 words of such sentence replaced
the words &ldquo;in privately negotiated transactions&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in"><FONT STYLE="font-size: 10pt">&ldquo;<B><I>Our shares
of common stock are quoted on the OTC Pink Open Market; and there currently is no active trading market for our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-indent: 40.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Our
shares of common stock are traded on the OTC Pink Open Market. There is currently no active trading market and for at least the
prior 3 years there has been no active trading market for our common stock. There can be no assurance that an active trading market
for our common stock will ever develop or if one develops it will be sustained. Furthermore, because our shares of common stock
are traded on the OTC Pink Open Market,&nbsp;the Selling Shareholders will only offer and sell their shares at a fixed price of
$3.00 per share until our shares are quoted on the OTC Bulletin Board or in the OTCQX or OTCQB marketplace of the OTC Link, and
, thereafter, at prevailing market prices or previously negotiated prices.&rdquo;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.75pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.25pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Given
                                         the nature and size of the transaction being registered, advise the staff of the company&rsquo;s
                                         basis for determining that the transaction is appropriately characterized as a transaction
                                         that is eligible to be made on a shelf basis under Rule 415(a)(1)(i).</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment. We have considered the factors set forth in Securities Act Rule Compliance and
Disclosure Interpretations (&ldquo;<U>C&amp;DI</U>&rdquo;) 612.09, regarding whether a purported secondary offering is really
a primary offering in which selling shareholders are acting as underwriters selling on behalf of an issuer as the basis for determining
that the transaction is appropriately characterized as a transaction that is eligible to be made on a shelf basis under Rule 415(a)(1)(i).&nbsp;
Based on the factors set forth in C&amp;DI 612.09,&nbsp;<U>the Company</U>&nbsp;respectfully submits that the Selling Shareholders
(as defined below), are not acting as underwriters or otherwise as a conduit for&nbsp;<U>the Company</U>&nbsp;and that the resale
of the 9,658,201 shares of&nbsp;<U>the Company</U>&rsquo;s common stock to be registered by the Registration Statement is not
an indirect primary offering being conducted by or on behalf of&nbsp;<U>the Company</U>. The Company respectfully submits that
the transaction set forth in the Registration Statement relates to the offering of securities solely by or on behalf of a person
other than the registrant, a subsidiary of the registrant or a person of which the registrant is a subsidiary, as discussed in
greater detail below, and therefore, is appropriately characterized as a transaction that is eligible to be made on a continuous
or delayed basis under Rule 415(a)(1)(i) promulgated under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 30.25pt; text-align: left"><FONT STYLE="font-size: 10pt">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Background.</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">On
July 24, 2017, pursuant to a Common Stock Purchase Agreement, dated as of July 24, 2017, by and among, the purchasers named therein
and the Company (the &ldquo;<U>2017 SPA</U>&rdquo;), the Company sold to such purchasers in a private placement (the &ldquo;<U>2017
Placement</U>&rdquo;) an aggregate 7,801,213 shares of its common stock at a purchase price of $0.66 per share, resulting in gross
proceeds to the Company of $4,731,872. Between November 2018 and March 29, 2019, pursuant to a Common Stock Purchase Agreement,
dated as of November 19, 2018, by and among, the purchasers named therein and the Company (the &ldquo;<U>2018 SPA</U>&rdquo; and
together with the 2017 SPA, collectively, the &ldquo;<U>SPAs</U>&rdquo;), the Company sold to such purchasers in a private placement
(the &ldquo;<U>2018 Placement</U>&rdquo; and together with the 2017 Private Placement, collectively, the &ldquo;<U>Private Placements</U>&rdquo;)
an aggregate of 1,856,988 shares at a purchase price of $2.25 per share, resulting in gross proceeds to the Company of $4,142,666.
At each closing of the 2 Private Placements, the purchasers paid the full purchase price for their Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Substantially
all of the 9,658,201 shares (each a &ldquo;<U>Share</U>&rdquo;), sold to purchasers (each a &ldquo;<U>Selling Shareholder</U>&rdquo;),
in the 2 Private Placements are included for resale in the Registration Statement. The Registration Statement was filed with the
Commission on June 27, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Section
2(a)(11) of the Securities Act defines an underwriter as&nbsp;&ldquo;any person who has purchased from an issuer with a view to,
or offers or sells for an issuer in connection with, the distribution of any security, or participates or has a direct or indirect
participation in any such undertaking, or participates or has a participation in the direct or indirect underwriting of any such
undertaking.&rdquo;&nbsp; The definition&rsquo;s phrase&nbsp;&ldquo;with a view to &hellip; distribution&rdquo;&nbsp;creates a subjective
standard regarding an investor&rsquo;s intent.&nbsp; As such, it is fact-specific.&nbsp; In determining intent, courts and the Commission
often look to evidence based on objective criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
prior no-action letters, the Staff has noted that the determination of &ldquo;underwriter&rdquo; status depends on all of the
facts and circumstances surrounding a particular transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
Staff also has stated that institutional investors generally should not be deemed to be underwriters with regard to the acquisition
of large amounts of securities, provided such securities are acquired in the ordinary course of the investor&rsquo;s business and that
the investor has no arrangement with any person to participate in the distribution of such securities.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 30.25pt; text-align: left"><FONT STYLE="font-size: 10pt">II.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Staff Guidance</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Rule
415(a)(1)(i) of the Securities Act provides that securities may be registered for an offering to be made on a continuous or delayed
basis in the future, provided that the registration statement pertains only to securities which are to be offered or sold solely
by or on behalf of a person or persons other than the registrant, a subsidiary of the registrant or a person of which the registrant
is a subsidiary. As stated in the Registration Statement, the Shares are being registered for resale or other disposition by each
of the Selling Shareholders only and no Shares or other securities are being registered for the Company. Proceeds from the sale
of any Share are solely for the account of the Selling Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">With
regard to the Staff&rsquo;s comment, we note that C&amp;DI 612.09 indicates that the issue of whether an offering is by or on
behalf of the issuer involves an analysis of facts beyond the entity that will receive the proceeds of the sale of securities
that are being registered. Specifically, C&amp;DI 612.09 states that consideration should be given to the following factors:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">how
                                         long the selling shareholders have held the shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the
                                         circumstances under which they have received them;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">their
                                         relationship to the issuer;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the
                                         amount of shares involved;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">whether
                                         the selling shareholders are in the business of underwriting securities; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">whether
                                         under all the circumstances it appears that the seller is acting as a conduit for the
                                         issuer.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 30.25pt; text-align: left"><FONT STYLE="font-size: 10pt">III.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Analysis</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">We
have analyzed the factors set forth in C&amp;DI 612.09 and believe that this analysis provides confirmation that the resale of
the Shares being registered for the Selling Shareholders in the Registration Statement is appropriately characterized as a transaction
that is eligible to be made on a shelf basis under Rule 415(a)(1)(i). The following is a summary of our analysis of these factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<B><I>How
Long the Selling Shareholders Have Held the Shares</I></B>. The longer the Shares have been held, the less likely it is that the
Selling Shareholders are acting as conduits (underwriters) for the Company and the more likely it is that the Selling Shareholders
acquired the Shares as long-term investors. All of the Selling Shareholders who purchased their respective Shares (7,801,213 in
the aggregate), in the 2017 Private Placement have held their Shares since July 24, 2017 (in excess of 2 years). All of the Selling
Shareholders who purchased their respective Shares (1,856,988 in the aggregate), in the 2018 Private Placement, have held their
Shares since November 19, 2018 (in excess of 8 months), except for 2 small Selling Shareholders, Solas Capital Partners II, LP
and William Meehan IRA, who purchased their 70,556 aggregate amount of Shares on approximately March 29, 2019. During the time
commencing on the July 24, 2017 closing date of the 2017 Placement through and including the date of this letter, to the Company&rsquo;s
knowledge, no Selling Shareholder has sold or otherwise transferred any of its Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
addition, the Selling Shareholders acquired the Shares knowing that there was no active trading market for the Shares and that
they could not liquidate their Shares. In fact, for at least the 3 year period prior to the date of this letter, to the Company&rsquo;s
knowledge, there has been no active trading market for the Shares and virtually no existing trading market in the Company&rsquo;s
shares of common stock on the OTC Pink Open Market. In short, no Selling Shareholder could have any reasonable expectation that
the market could absorb even a small amount of Shares, let alone 9,658,201 Shares, which provides further evidence that none of
the Selling Shareholders intended to act and/or are acting as conduits (underwriters) for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Substantially
all of the Shares included in the Registration Statement have been held by the Selling Shareholders for approximately 2 years
or 8 months (as applicable). The Selling Shareholders held their Shares for 13 months or 3 months (as applicable) prior to the
filing of the Registration Statement. These lengthy holding periods are substantially longer than the periods required by the
Staff for valid&nbsp;&ldquo;<I>PIPE</I>&rdquo;&nbsp;(private-investment, public-equity) transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
a prior C&amp;DI, the Staff codified its&nbsp;<I>&ldquo;PIPEs&rdquo;</I>&nbsp;interpretation (the &ldquo;<U>PIPEs Interpretation</U>&rdquo;)
by providing in relevant part that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<I>In
a PIPE transaction (private-investment, public-equity), the staff will not object if a company registers the resale of securities
prior to their issuance if&nbsp;the company&nbsp;has completed a Section 4(2)-exempt sale of the securities (or in the case of
convertible securities, of the convertible security itself) to the investor, and the investor is at marketrisk at the time of
filing of the resale registration statement&hellip;.The closing of the private placement of the unissued securities must occur
within a short time after the effectiveness of the resale registration statement.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
PIPEs Interpretation contemplates that a valid secondary offering could occur immediately following the closing of&nbsp;the placement.&nbsp;
Since no holding period is required for a PIPE transaction to be a valid secondary offering, by definition a holding period of
2 years or 8 months as indicated above should be sufficient for a valid secondary offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
above lengthy holding periods and the non-liquid market for the Shares indicates that the Shares were not acquired by the Selling
Shareholders with a &ldquo;<I>view to distribution</I>.&rdquo; The Selling Shareholders have borne market risk associated with
owning the Shares since they purchased their Shares at a fixed price without the ability to influence the consummation of the
transaction or the purchase price per Share. It is our understanding that the Staff has become increasingly concerned with transactions
that include significant price adjustments and ratchet provisions, which was not the case here. This was a sale of common stock
only, whereas the transactions that have historically concerned the Staff have involved convertible securities containing price
adjustment mechanisms. These circumstances distinguish potential resales of Shares by the Selling Shareholders from a primary
offering by the Company or an underwriter acting on its behalf. Although it should be noted that in the SPA for the 2018 Placement,
the purchasers negotiated for a limited anti-dilution provision, such provision terminated by its terms prior to the filing of
the Registration Statement and no additional securities of the Company were issued to any Selling Shareholder or any other person
pursuant to such provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<B><I>The
Circumstances Under Which the Selling Shareholders Received the Shares</I></B>. All of the Selling Shareholders purchased their
Shares in a bona fide, arms-length private placement transactions pursuant to Section 4(a)(2) of the Securities Act and/or Rule
506 of Regulation D promulgated thereunder. The Selling Shareholders who purchased their Shares in the 2017 Placement received
no registration rights with respect to their Shares. With regard to the Selling Shareholders who purchased their Shares in the
2018 Placement, the Company agreed to use its commercially best efforts to file a registration statement with the SEC within 90
days after the final closing of the 2018 Placement, which date was June 29, 2019, two days after the date that the Company filed
the Registration Statement with the Commission. The registration rights were a condition subsequent to the purchase of the Shares
by the Selling Shareholders not a condition precedent; and did not require that the Registration Statement become effective on
a specified date. Moreover, such registration rights contained no required payment or share issuance if the Company failed to
meet any filing or effectiveness deadlines. In most PIPEs transactions, purchasers require the resale registration statement be
filed immediately or shortly following closing (typically 30 days after the closing date), and be declared effective shortly thereafter
(typically 90 days after the closing date) and contain substantial penalties if the issuer fails to meet such deadlines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
SPAs contain provisions that are relevant to each Selling Shareholder&rsquo;s intent to resell the Shares. Each Selling Shareholders
represented and warranted in the SPAs that (i) it was acquiring the Shares for investment for its own account, not as a nominee
and not with a view to the resale or distribution of any part thereof, and that it had no present intention of selling, granting
any participation in, or otherwise distributing its Shares, (ii) it had no contract, understanding, agreement or arrangement with
any person to sell, transfer or grant any participation to any such persons or to any 3<SUP>rd</SUP> person with respect to its
Shares. In the SPAs, each Selling Shareholder also made other customary investment and private placement representations to the
Company. The Company is neither aware of any evidence that would indicate that these representations were false nor aware of any
evidence that any of the Selling Shareholders had any plan to act in concert with a third party or to effect a distribution of
Shares. In addition, the Company is not aware of any evidence that would indicate that a distribution would occur if the Registration
Statement is declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Substantially
all of the gross cash proceeds from the Company&rsquo;s sale of the Shares issued at the closing of the 2 Private Placements went
directly to the Company. None of the Selling Shareholders received any of such proceeds nor any commission or other compensation
from the Company in connection with the 2 Private Placements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">These
circumstances are quite distinct from those involving a primary offering by or on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt"><B><I>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<B><I>The
Relationship of the Selling Shareholders to the Company</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#9;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The
Affiliated Selling Shareholders who may be deemed Affiliates of the Company</U>.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         following four (4) Selling Shareholders may be deemed affiliates (as defined in the Securities
                                         Act of 1933, as amended), of the Company: James E. Besser, Manchester Explorer L.P. (&ldquo;<U>Manchester</U>&rdquo;),
                                         JEB Partners LP (&ldquo;<U>JEBP</U>&rdquo; and together with Manchester, the &ldquo;<U>JEB
                                         Funds</U>&rdquo;) and the Paul DiPerna Trust (the &ldquo;<U>DiPerna Trust</U>&rdquo;
                                         and together with Mr. Besser and the JEB Funds, collectively, the &ldquo;<U>Affiliate
                                         Selling Shareholders</U>&rdquo;).</FONT><FONT STYLE="font: 10pt Symbol"><SUP>*</SUP></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         Affiliate Selling Shareholders purchased and currently hold 6,326,061 Shares of the 9,658,201
                                         Shares sold to Selling Shareholders in the 2 Private Placements. Column 3 of the below
                                         table and the footnotes thereto, set forth each Affiliate Selling Shareholder&rsquo;s
                                         amount of Shares purchased in the 2 Private Placements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Symbol"><SUP>*</SUP></FONT><FONT STYLE="font-size: 10pt">
<FONT STYLE="font-family: Times New Roman, Times, Serif">Morgan Frank is a director of the Company and may be deemed an affiliate
of the JEB Funds. Mr. Frank is 47 years old, graduated from college in 1994 and has been living in his own residence and supporting
himself for over 25 years. The trustees of the Frank Family Trust (the &ldquo;<U>FF Trust</U>&rdquo;) are Mr. Frank&rsquo;s mother
and father. The FF Trust holds and is the registered owner of 489,999 Shares, of which it purchased 378,778 Shares in the 2017
Placement and 111,111 Shares in the 2018 Placement. The FF Trust is a Selling Shareholder and all such 489,999 Shares are being
registered for resale in the Registration Statement. As provided in the trust documents, Mr. Frank is not a trustee of the FF
Trust and does not have sole or shared voting power or investment power of any of such 489,999 Shares. As a result, the Company
does not believe the FF Trust is an affiliate of Mr. Frank or the Company. As a result, the FF Trust is not being viewed by the
Company as an Affiliate Selling Shareholder. Mr. Frank disclaims beneficial ownership of all 489,999 Shares held by the FF Trust.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 8.65pt; text-indent: -8.65pt">Name of <BR>
Affiliate <BR>
Selling<BR>Shareholder</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned Pre-<BR>
Offering (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Owned<BR>Beneficially<BR>Pre-<BR> Offering (1)(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares of<BR>Common<BR>Stock to be<BR>offered for<BR>Affiliate <BR>
Selling<BR>Shareholder&rsquo;s<BR>account (3)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>Post-<BR> Offering (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% <BR>
Beneficially<BR>Owned<BR>Post-<BR> Offering (1)(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; text-indent: -8.65pt; padding-left: 8.65pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">James E. Besser</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">6,384,691</TD><TD STYLE="width: 1%; text-align: left">(4)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">35.73</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">88,889</TD><TD STYLE="width: 1%; text-align: left">(5)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">6,295,802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">35.23</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">JEB Partners, LP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,384,691</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.73</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917,576</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,467,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.60</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Manchester Explorer, LP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,384,691</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.73</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,016,566</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,368,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.66</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Paul DiPerna Trust</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,638,117</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42.74</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,030</TD><TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,335,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41.05</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Beneficial ownership includes shares of common stock as to which a person or group has sole or shared voting power or investment power. Shares of common stock subject to options, warrants or other convertible securities that are exercisable or convertible currently or within 60 days, are deemed outstanding for purposes of computing the number of shares beneficially owned and percentage ownership of the person or group holding such options, warrants or convertible securities, but are not deemed outstanding for computing the percentage of any other person.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Percentages are based on 17,870,261 shares of common stock outstanding as of June 30, 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Represents shares of our common stock issued exclusively in the 2017 Placement and the 2018 Placement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes (i) 180,830 shares directly held by Mr. Besser, which shares were received in the Acquisition in exchange for Mr. Besser&rsquo;s shares of Quasuras; (ii) 88,889 shares directly held by Mr. Besser who purchased such shares in the 2018 Placement; (iii) 4,545,455 shares held by Manchester who purchased such shares in the 2017 Placement; (iv) 471,111 shares held by Manchester who purchased such shares in the 2018 Placement; (v) 757,576 shares held by JEB Partners who purchased such shares in the 2017 Placement; (vi) 160,000 shares held by JEB Partners who purchased such shares in the 2018 Placement; and (vii) 180,830 shares held by Mr. Frank, which shares were received in the Acquisition in exchange for Mr. Frank&rsquo;s shares of Quasuras. Mr. Besser as the managing member and Mr. Frank as the portfolio manager and consultant of Manchester Management, LLC (&ldquo;<U>MMC</U>&rdquo;), the general partner of Manchester and JEB Partners, have shared voting and dispositive power over shares held by Manchester and JEB Partners. Such person disclaims beneficial ownership of all shares not directly held by such person and this letter shall not be deemed an admission that such person is the beneficial owner of these shares for any purpose, except to the extent of such person&rsquo;s pecuniary interest therein. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes shares purchased in the 2018 Placement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes (i) 757,576 shares directly held and purchased in the 2017 Placement; and (ii) 160,000 shares directly held and purchased in the 2018 Placement. Such person disclaims beneficial ownership of all shares not directly held by such person and this letter shall not be deemed an admission that such person is the beneficial owner of these shares for any purpose, except to the extent of such person&rsquo;s pecuniary interest therein. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding-bottom: 8pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(7)</FONT></td>
    <TD STYLE="padding-bottom: 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes
    (i) 4,545,455 shares purchased by Manchester in the 2017 Placement; and (ii) 471,111 shares purchased by Manchester in the
    2018 Placement. Such person disclaims beneficial ownership of all shares not directly held by such person and this letter
    shall not be deemed an admission that such person is the beneficial owner of these shares for any purpose, except to the extent
    of such person&rsquo;s pecuniary interest therein. </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding-bottom: 8pt; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(8)</FONT></td>
    <TD STYLE="padding-bottom: 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Includes
    (i) 303,030 shares held directly by the Paul DiPerna Trust, which shares were purchased by the Paul DiPerna Trust in the 2017
    Placement; (ii) 7,270,400 shares acquired by Mr. DiPerna in the Acquisition in exchange for his shares of Quasuras; and (iii)
    64,687 shares issuable upon exercise of fully vested stock options issued to Mr. DiPerna under our ESOP (as defined below).
    Mr. DiPerna is our Chairman, Chief Executive Officer, Chief Financial Officer, Secretary and Director. Such person disclaims
    beneficial ownership of all shares not directly held by such person and this letter shall not be deemed an admission that
    such person is the beneficial owner of these shares for any purpose, except to the extent of such person&rsquo;s pecuniary
    interest therein. </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(9)</FONT></td>
    <TD STYLE="padding-bottom: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Include
    shares purchased in the 2017 Placement.</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.2in; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="width: 0.05in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Although
the 4 Affiliate Selling Shareholders may be deemed affiliates of the Company, the Staff has clarified that affiliates, including
those that hold a large percentage of outstanding shares, are not per se disqualified from undertaking secondary offerings.&nbsp;
Please see Securities Act Forms C&amp;DI 216.14 (&ldquo;Secondary sales by affiliates may be made under General Instruction I.B.3
to Form S-3, even in cases where the affiliate owns more than 50% of the issuer&rsquo;s securities, unless the facts and circumstances
indicate that the affiliate is acting as an underwriter or by or on behalf of the issuer&rdquo;).&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul
                                         DiPerna is the Chairman and Chief Executive Officer of the Company. Mr. DiPerna is the
                                         trustee of the DiPerna Family Trust. As set forth in Mr. DiPerna&rsquo;s biography in
                                         the &ldquo;Management&rdquo; section of the Registration Statement, Mr. DiPerna has over
                                         30 years of experience in developing, designing, obtaining FDA approval, managing and
                                         commercializing medical devices, including insulin and hospital based pumps while holding
                                         a variety of executive and non-executive positions while working for such industry leaders
                                         as Baxter Healthcare, Inc. and Tandem Diabetes Care, Inc., in addition to other public
                                         and private entities. On July 24, 2017, the Company acquired Quasuras, Inc. (&ldquo;<U>Quasuras</U>&rdquo;),
                                         of which Mr. DiPerna owned 93.33% and was the sole officer and director. As consideration
                                         for such acquisition, the Company issued to Mr. DiPerna 7,270,400 shares of common stock.
                                         To demonstrate his commitment to the Company, in the 2017 Placement, the DiPerna Trust
                                         purchased 303,030 Shares. As of the date hereof, Mr. DiPerna and the DiPerna Trust beneficially
                                         own 7,588,117 shares of common stock of the Company (42.38% of the issued and outstanding
                                         common stock). To date, neither Mr. DiPerna nor the DiPerna Trust has sold any shares
                                         of common stock. The 303,030 Shares the DiPerna Trust is registering for resale under
                                         the Registration Statement represents only 3.13% of the Shares purchased by all Selling
                                         Shareholders in the 2 Private Placements, less than 4% of the common stock beneficially
                                         owned by Mr. DiPerna and the DiPerna Trust and less than 3.38% of the issued and outstanding
                                         common stock of the Company. Even if the DiPerna Trust were to sell all of the 303,030
                                         Shares covered by the Registration Statement, the DiPerna Trust would continue to beneficially
                                         own 40.83% of the issued and outstanding common stock of the Company.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">It
                                         is also significant to note that as indicated above, Mr. DiPerna acquired 7,588,117 shares
                                         of common stock of the Company in consideration for his sale of Quasuras to the Company.
                                         Notwithstanding such substantial ownership in the Company, Mr. DiPerna, through the DiPerna
                                         Trust, acquired such additional 303,030 Shares in the 2017 Placement to further show
                                         his belief and commitment to the Company. All of such Shares were purchased for cash
                                         similar to each other investor. This further demonstrates that the actions of Mr. DiPerna
                                         do not equate to those of an underwriter in a primary offering.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Manchester
                                         and JEBP (the JEB Funds) were formed in 2004 and 1999, respectively. The JEB Funds perform
                                         due diligence and invest in public companies in a wide range of industries including
                                         life sciences, biotechnology and medical devices. Since 2013, Manchester and JEBP have
                                         collectively made over 30 direct investments in various public entities ranging in dollar
                                         sizes from $200,000 to $5,000,000. It is not uncommon for the JEBP Funds to take or seek
                                         to take large position portfolio companies that are illiquid and/or have limited liquidity
                                         and, following their initial purchases, add on in subsequent rounds. Because of its general
                                         long-term investment philosophy, the JEB Funds are very selective in the direct investments
                                         they make. They perform extensive due diligence on each direct investment they make,
                                         including background checks of management, the market for the issuer&rsquo;s business
                                         and the industry that the issuer operates in.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Generally,
                                         the JEB Funds&rsquo; direct investments are long-term commitments to their portfolio
                                         companies. Their investment philosophy is based on investing in companies that they believe
                                         have significant long-term growth opportunities.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Often
                                         their direct investments are to pre-revenue, development stage companies. Because of
                                         this, these companies have limited, if any, market coverage and trading in their shares.
                                         While this factor may be significant to certain types of investment funds and investors,
                                         generally, this fact is not necessarily a significant factor to the JEB Funds as they
                                         are investing based on management and the fundamentals of their portfolio company and
                                         believe that if management and the company properly execute on the business plan, the
                                         market price of the stock and liquidity opportunities will eventually reflect the value
                                         of the issuer in the long term. This investment philosophy is extremely important when
                                         considering whether Mr. Besser and the JEB Funds are acting as conduits or underwriters
                                         on behalf of the Company. Nothing could be farther from the truth. Their purchase of
                                         the Shares is exactly in line with the JEB Funds historic direct investments and their
                                         long-term value investment philosophy. Their investment in the Shares was based upon
                                         extensive due diligence of Mr. DiPerna, the diabetes market and such person&rsquo;s view
                                         of the market and need for an insulin pump similar to one that the Company is developing.
                                         They initially purchased Shares at $0.66 per Share and 15 months later at $2.25 per Share.
                                         To date, they have sold no Shares and knew when they purchased their Shares that there
                                         was no historic or current liquidity for the Shares. These factors, regardless of any
                                         additional factors, clearly demonstrate that Mr. Besser and the JEB Funds are not conduits
                                         or underwriters for the Company, but are long-term investors.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr.
                                         Besser met Mr. DiPerna in approximately November, 2016. Prior to such time, neither Mr.
                                         Besser nor any of the JEB Funds knew or had any relationship with Mr. DiPerna, Quasuras
                                         or any of their affiliates.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Similar
                                         to nearly all other Selling Shareholders, all of the Shares purchased by Mr. Besser and
                                         the JEB Funds in the 2 Private Placements, are being registered for resale in the Registration
                                         Statement. It is significant to note, however, that such registration is not indicative
                                         of a desire to sell and/or distribute any such Shares, nor is it indicia of a primary
                                         offering. A significant reason the JEB Funds desire to have their Shares included in
                                         the Registration Statement is that, similar to other investment funds whose investment
                                         mandate is publicly traded companies, the JEB Funds require &ldquo;liquid&rdquo; securities
                                         in order to be able to assess and place a value on such Shares. Without registration,
                                         the Shares held by the JEB Funds are viewed as being illiquid even though a portion can
                                         be sold in any three month period under Rule 144. In the current economic environment,
                                         funds similar to the JEB Funds are under pressure to structure their investments so that
                                         their value is more quantifiable and predictable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">It
is also significant to note that as set forth in Response 5 of this letter, Manchester, on April 26, 2017 purchased 2,900,000
shares of common stock from the Company for $375,000, or $0.13 per share. Manchester, as a condition to closing of the acquisition
by the Company of Quasuras and the 2017 Placement agreed to sell all such 2,900,000 shares back to the Company for <U>no</U> <U>gain</U>,
simply a return of his original purchase price. Because the Company wanted to use its limited available funds to fund operations,
Manchester agreed to forego payment of such purchase price in cash and accepted 568,181 Shares in the 2017 Placement instead.
However, as set forth above, the $375,000 original purchase price for such 2,900,000 shares represented a purchase price of $0.13
per share and the purchase price paid by Manchester in the 2017 Placement was $0.66 per share. Further to the above, this behavior
is indicative of a long-term investor and not of a conduit or underwriter acting on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Substantially
all of the 6,384,691 shares of common stock beneficially owned by Mr. Besser and each of the JEB Funds in the Company are Shares
purchased by such persons in the 2 Private Placements. Other than as set forth in Response 5 below, the Company has indicated
that to date, neither Mr. Besser nor any of the JEB Funds have sold any shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Each
of the 4 Affiliate Selling Shareholders, as well as Messrs DiPerna and Frank, have represented that they are not in the business
of underwriting securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">We
also note that many of the investments the Commission has historically been concerned with involve the use of beneficial ownership&nbsp;&ldquo;<I>blockers</I>&rdquo;
to maintain an ownership percentage below the thresholds for triggering the filing of Schedule 13D and Schedule 13G filings for
Forms 3 and 4 pursuant Section 16 of the Securities and Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;)
and being subject to the clawback of Section 16 of &ldquo;short swing profits.&rdquo;&nbsp; Here, none of the 4 Affiliate Selling
Shareholders is subject to any such beneficial ownership&nbsp;&ldquo;<I>blockers.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To&nbsp;the
Company&rsquo;s knowledge, there is no legal or business relationship between the other Selling Shareholders and the 4 Affiliate Selling
Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Other
than as discussed in the footnotes to the table above, to the Company&rsquo;s knowledge, there are no relationships between the
Affiliate Selling Shareholders.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each
                                         of the Affiliate Selling Shareholders has held their respective shares for (i) over 2
                                         years with regard to Shares acquired in the 2017 Placement, and (ii) over 8 months with
                                         regard to Shares acquired in the 2018 Placement.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         Affiliate Selling Shareholders are not acting on behalf of the Company with respect to
                                         the Shares, the Company has no understanding or other contractual, legal or other relationship
                                         with any of the Affiliate Selling Shareholders that would control the timing, nature
                                         or amount of their resales of their Shares, and the Company will receive no proceeds
                                         from the sale, if any, of any of their Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
facts set forth above support the view that the relationship of each of the 4 Affiliate Selling Shareholders with the Company
has been that of (depending upon the particular Affiliate Selling Shareholder) either a long-term investor; or seasoned entrepreneurial
executive officer/director of a development stage public company attempting to build a long term and sustainable business to offer
hope to millions of long suffering diabetics, in line with such persons 30 plus years business history, experience and skill set.
Such facts do not support the view that the relationship of such persons to the Company is that of underwriters or conduits of
the Company in a primary securities offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>The
Other Selling Shareholders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Except
with respect to the 4 Affiliate Selling Shareholders, prior to their respective initial purchases of Shares in the 2 Private Placements,
none of the other 28 Selling Shareholders (each an &ldquo;<U>Other Selling Shareholder</U>&rdquo;) had a prior relationship with
the Company. The number of Shares purchased by the Other Selling Shareholders in the 2 Private Placements ranged from a high of
489,999 Shares representing beneficial ownership of 2.75% of the Company&rsquo;s issued and outstanding shares of common stock
to 8,882 Shares representing beneficial ownership of less than 1% of the Company&rsquo;s issued and outstanding common stock.
To the knowledge of the Company, all securities of the Company held by the Other Selling Shareholders consist solely of Shares
purchased in the 2 Private Placements. To the Company&rsquo;s knowledge, no Other Selling Shareholders has sold or otherwise transferred
any of its Shares. None of the Other Selling Shareholders is subject to &ldquo;blockers,&rdquo; and, other than as set forth in
the &ldquo;Selling Shareholders&rdquo; section of the Registration Statement, no such persons have relationships with each other
or the 4 Affiliate Selling Shareholders. Such Other Selling Shareholders have held their Shares for the lengthy time periods set
forth above, are not acting on behalf of the Company and other than the basic post-closing registration rights, do not have any
understanding or other contractual relationship with the Company concerning the timing, nature or amount of their resale of Shares
and the Company will not receive any proceeds from any resales of such persons&rsquo; Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&#9;D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>The
Amount of Shares Involved</I></B>. As of the date hereof,&nbsp;<U>the Company</U>&nbsp;has 17,870,261 shares of common stock outstanding,
of which approximately 961,660 shares were held by persons other than the Selling Shareholders, affiliates of&nbsp;<U>the Company</U>&nbsp;and
affiliates of the Selling Shareholders.&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">It
                                         is our understanding that several years ago the Staff became increasingly concerned about
                                         public resales of securities purchased in&nbsp;<I>&ldquo;toxic&rdquo;</I>&nbsp;transactions.&nbsp;
                                         The Staff believed that public investors did not have an appropriate understanding as
                                         to the nature of the investment being made or the negative impact that such transactions
                                         could have on the market prices of the issuers involved.&nbsp; In many of these&nbsp;<I>&ldquo;toxic&rdquo;</I>&nbsp;transactions,
                                         an issuer would commit to issuing shares at a conversion price that floated in accordance
                                         with the market prices of the underlying common stock.&nbsp; When the deals were announced,
                                         the stock prices typically fell with the result that the issuer ended up issuing significant
                                         blocks of stock -- in many cases well in excess of 100% of the shares previously outstanding.&nbsp;
                                         In these toxic situations, existing investors or investors who purchased shares after
                                         the announcement of the transaction frequently faced unrelenting downward pressure on
                                         the value of their investments.&nbsp; In too many of these cases, the shares held by
                                         non-participants in these transactions were ultimately rendered worthless.&nbsp; In order
                                         to combat the effects of these toxic transactions, the Office of Chief Counsel and the
                                         Staff began to look at ways to discourage toxic transactions and to limit the impact
                                         of these transactions.&nbsp; One way to do so was to limit the ability of the investors
                                         in those transactions to have the resale of their shares registered.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         order for the Staff to determine that the offering is really being made on behalf of
                                         the issuer, by definition the Staff must conclude that the selling shareholders are seeking
                                         to effect a distribution of the shares.&nbsp; However, if the Staff&rsquo;s concern is that
                                         a distribution is taking place, the number of shares being registered should be one of
                                         the less important factors in the Staff&rsquo;s analysis.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Focusing
                                         on the number of shares being registered in relation to the shares outstanding or the
                                         public float has a disproportionate impact on smaller public companies -- exactly those
                                         issuers who have very limited options to raise funds -- and seems contrary to the SEC&rsquo;s
                                         public commitment to small business issuers, as evidenced by its actions to streamline
                                         small business capital raising (i.e. providing reporting and regulatory relief to smaller
                                         reporting companies and extending Form S-3 eligibility to issuers with market capitalizations
                                         under $75 million in certain circumstances).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">A
                                         focus solely on numbers of shares to be registered also ignores a fundamental aspect
                                         of these transactions: institutional investors in PIPEs are funding business plans and
                                         strategic initiatives, not looking to illegally distribute stock.&nbsp; By focusing on
                                         the percentage of the public float or the percentage of the shares outstanding, the Staff
                                         unfairly penalizes smaller companies.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Limiting
                                         the number of shares being registered does not effect any significant change in the circumstances
                                         of a proposed offering.&nbsp; If the Selling Shareholders are acting as a mere conduit
                                         for&nbsp;<U>the Company</U>, cutting back on the number of shares being sold only makes
                                         it easier for them to accomplish their goal by cutting back on the number of shares they
                                         have to sell.&nbsp; It doesn&rsquo;t change the investment intent of the Selling Shareholders
                                         or the ability of the Selling Shareholders to effect a distribution if, in fact, that
                                         was their intent.&nbsp; Based upon various facts set forth herein including, among other
                                         facts, that the Shares sold in the 2 Private Placements were only common stock and not
                                         securities with price adjustments and the lack of any active trading market in the common
                                         stock to accommodate even a sale of a small portion of the Shares, it is evident that
                                         the purchasers were not acting as underwriters.&nbsp; In fact, the significant number
                                         of shares purchased is evidence of that non-action.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Regardless
                                         of percentage, it is important to note that the amount of shares being registered is
                                         only one factor cited in C&amp;DI 602.09, and is not controlling.&nbsp; C&amp;DI 602.12
                                         describes a scenario where a holder of well over one-third of the outstanding stock is
                                         able to effect a valid secondary offering.&nbsp; The interpretation states, in relevant
                                         part, that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&ldquo;A
controlling person of an issuer owns a 73% block.&nbsp; That person will sell the block in a registered &lsquo;at-the-market&rsquo;
equity offering.&nbsp; Rule 415(a)(4), which places certain limitations on &lsquo;at the-market&rsquo; equity offerings, applies
only to offerings by or on behalf of&nbsp;<U>the registrant</U>.&nbsp; A secondary offering by a control person that is not deemed
to be by or on behalf of&nbsp;<U>the registrant</U>&nbsp;is not restricted by Rule 415 (a)(4).&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
addition, a C&amp;DI regarding the use of Form S-3 to effect a secondary offering, provides:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&ldquo;A
number of persons have asked whether Form S-3 is available for secondary offerings to be made by affiliates of the issuer.&nbsp;
The concern was that because the seller was an affiliate, the Division staff might consider the secondary offering a sale on behalf
of the issuer and, in reality, a primary offering requiring the affiliate-registrant to meet the more stringent Form S-3 standards
applicable to primary offerings by issuers.&nbsp; The Division staff had indicated, however, that secondary sales by affiliates
may be made under General Instruction I.B.3.&nbsp; to Form S-3 relating to secondary offerings, even in cases where the affiliate
owns more than 50% of the issuer&rsquo;s securities, unless the facts&nbsp;<U>clearly</U>&nbsp;indicate that the affiliate is acting
as an underwriter on behalf of the issuer.&nbsp; However, if the percentage is too high, it must be examined on a case-by-case
basis.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">These
interpretive positions make clear that holders of well in excess of one-third of the public float can effect a valid secondary
offering of its shares unless other facts -- beyond the mere level of ownership -- indicate that the affiliate is acting as a
conduit for the issuer. In this case, we respectively submit, such facts are not present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Moreover,
there is no evidence that a distribution would occur if the Registration Statement is declared effective. The Company has no knowledge
and believes that the Selling Shareholders have no agreements or understandings with any person with respect to the distribution
of their Shares. We note that under Rule 100(b) of Regulation M, a &ldquo;distribution&rdquo; is defined to require special selling
efforts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;[A]n
offering of securities, whether or not subject to registration under the Securities Act, that is distinguished from ordinary trading
transactions by the magnitude of the offering&nbsp;<I>and the presence of special selling efforts and special selling methods</I>.&rdquo;
(emphasis added)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Accordingly,
the Company has not been advised, and is not otherwise aware, of any special selling efforts or selling methods that have been
or will take place in connection with the filing of the Registration Statement. Nor is there any evidence that any of the Selling
Shareholders have conducted or intend to conduct any road shows or have taken any other actions to condition or &ldquo;prime&rdquo;
the market for their Shares. The mere size of a potential offering does not make a proposed sale a &ldquo;distribution,&rdquo;
and the Company believes that the other factors discussed in this letter, such as the Selling Shareholders&rsquo; represented
investment intent, the identity of the Selling Shareholders and the relationships of the Selling Shareholders to the Company,
support the characterization of the registered transaction as a secondary offering of the Shares and not of a primary offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><I>&#9;</I></B>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Whether
the Selling Shareholders are in the Business of Underwriting. </I></B>To the knowledge of <U>the Company and representations
of each of the Selling Shareholders made to the Company</U>, none of the Selling Shareholders is in the business of underwriting
securities.&nbsp; At no time has any Selling Shareholder been affiliated with or acted as securities broker-dealers or representatives
thereof.&nbsp; Certain of the Selling Shareholders are investment funds (including the JEB Funds) focused on making equity and
debt, control and non-control investments across broad and diverse industries.&nbsp; Furthermore, as set forth above, each of
the Selling Shareholders represented at the time of purchase of the Shares that it had no agreement or understanding to resell
or distribute the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><I>&#9;F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
Under all Circumstances It Appears the Selling Shareholders are Acting as a Conduit for the Company.&nbsp;&nbsp;&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">This
                                         transaction has none of the hallmarks of transactions which the Staff has historically
                                         had concerns with.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Specifically
                                         and as discussed above, the Company believes that the following factors weigh in favor
                                         of the conclusion that none of the Selling Shareholders are acting as conduits or underwriters
                                         for the Company in a primary offering but that the Selling Shareholders are acting solely
                                         for themselves as investors and that the transaction is a secondary offering by Selling
                                         Shareholders and the transaction covered by the Registration Statement is a valid secondary
                                         offering:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         Shares to be registered pursuant to the Registration Statement were issued in private
                                         placements to 32 selling shareholders&nbsp; in connection with the bona fide decision
                                         of the Selling Shareholders to engage in a long-term investment;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
                                         Selling Shareholder has represented in the SPAs that&nbsp;it was acquiring its Shares
                                         as principal for its own account and not with a view to or for distributing or reselling
                                         the shares;</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         Selling Shareholders have and continue to bear the full economic risk of their investment
                                         in the Shares by holding their Shares for either&nbsp;2 years or 8 months;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
                                         of the extremely limited and illiquid market for the common stock, the Selling Shareholders
                                         when purchasing their Shares did not have any expectation of being able in&nbsp; the
                                         foreseeable future to sell even a limited number of their&nbsp;Shares much less over
                                         9,658,201&nbsp;Shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
                                         connection with their purchase of their Shares, the Selling Shareholders did not receive
                                         any placement fees or commissions from the Company in connection therewith;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Company filed the Registration Statement to comply with the registration rights set forth
                                         in the SPAs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Company&nbsp;will not receive any of the proceeds from the sale of any of the Shares
                                         by the Selling Shareholders;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Selling Shareholders are acting on their own behalf and not on behalf of the Company;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         Staff&rsquo;s prior position in C&amp;DI 116.15 concludes that affiliates may validly
                                         engage in secondary offerings including even if they own over 50% of the issuers outstanding
                                         shares;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         4 Affiliate Selling Shareholders&rsquo; histories, business and actions relating to the
                                         Shares do not demonstrate any characteristics of acting as a conduit of the Company,
                                         rather they&nbsp;demonstrate exactly who they are and their intentions with regard to
                                         the Shares- - long term investors and/or executive officers/directors of a company desiring
                                         to&nbsp;build&nbsp; a long term and sustainable business exactly in line with their historic&nbsp;&nbsp;career
                                         paths,&nbsp;business skills&nbsp;&nbsp;and history;&nbsp;&nbsp;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Selling Shareholders have no underwriting or similar relationships with&nbsp;the Company,
                                         and are not in the business of underwriting securities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         amount of Shares involved is within the scope permissible by the Commission; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">there
                                         were no beneficial ownership blockers and, in contrast to deals where such provisions
                                         are used to prevent purchasers from being subject to the provisions of Section 16, here
                                         all of the Selling Shareholders voluntarily subjected themselves to Section 16; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
                                         the number of shares of the Company&rsquo;s common stock held by persons other than the
                                         affiliates of the Company, the Selling Shareholders and affiliates thereof, is substantial,
                                         there are clear explanations and reasons for such, including that Mr. Besser and the
                                         JEB Funds who beneficially own 6,381,691 shares of common stock purchased most of such
                                         shares in the 2 Private Placements as long term investors and to help fund the initial
                                         and continuing operations of the Company and the Shares are being registered in large
                                         part for fund valuation purposes; and that Mr. DiPerna and the DiPerna Trust beneficially
                                         own 7,558,117 shares of common stock but substantially all of such shares were issued
                                         to Mr. DiPerna for the acquisition of his company, which is the sole business of the
                                         Company; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
                                         is no evidence to suggest that any of the Selling Shareholders are acting in concert
                                         to effect a coordinated distribution of the Shares.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Finally,
the Company also notes that this is not a &ldquo;toxic&rdquo; PIPE transaction or transaction involving warrants or convertible
notes. Rather, this is a registration involving a finite number of shares&nbsp;that have been held for a substantial time period
and in all likelihood will be held for a substantially longer period of time.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         totality of the facts and circumstances surrounding the transaction&nbsp;demonstrates
                                         that the Selling Shareholders are not acting as a conduit in a distribution to the public.
                                         Rather, they are acting for their own account as long-term investors in an arms-length
                                         transaction with the Company.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>The
                                         Company</U>&nbsp;respectfully submits that, in light of all of the circumstances, the
                                         Selling Shareholders are not acting as an underwriter on behalf of, or as a conduit for,&nbsp;<U>the
                                         Company</U>&nbsp;and the proposed resale of the shares by the Selling Shareholders as
                                         contemplated by the Registration Statement is appropriately characterized as a secondary
                                         offering that is eligible to be made on a delayed or continuous basis under Rule 415(a)(1)(i)
                                         rather than a primary offering.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Should
                                         the Commission disagree with the foregoing conclusion,&nbsp;<U>the Company</U>&nbsp;would
                                         welcome an opportunity to further discuss such conclusion with the Commission.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Prospectus
Summary, page 2</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.75pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.25pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         explain clearly each material step you must take to reach commercialization of your technology
                                         to address the markets mentioned on page 26. Include the material hurdles before you
                                         are able to address these markets. If such detail is not appropriate for your prospectus
                                         summary, carefully consider the information that is the most significant, and briefly
                                         highlight that information in the summary and include more detailed disclosure elsewhere
                                         in your prospectus</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
response to the Staff&rsquo;s request, we have added the following to the &ldquo;Prospectus Summary&rdquo; section of the Registration
Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;While we have
substantially completed the general engineering and mechanical aspects of our current insulin pump prototype, prior to, commercializing,
we still must successfully complete a number of material steps including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Continue
                                         to modify, refine and finalize our prototype so that it:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">meets
                                         the general needs and preferences of our almost pumper target market based in large part
                                         on the recommendations from Kirk Brote resulting from their analysis of feedback and
                                         other information obtained from almost pumpers and their caregivers </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">meets
                                         the general guidelines of third party payors, private and public insurance companies,
                                         preferred provider organizations and other managed care providers with particular focus
                                         on the guidelines established by the Center for Medicare and Medicaid Services, CMS which
                                         administrates the United States Medicare program. To assist us in making such modifications
                                         and refinements, we have retained PrecisionXtract Inc., an independent consulting firm,
                                         who is focused on ensuring that our product satisfies the coverage and reimbursement
                                         criteria of such third party payors.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Continue
                                         to work closely with, Susan Finnerman, of Regulatory Compliance Experts, Inc., referred
                                         to in this prospectus as &ldquo;our FDA regulatory consultant,&rdquo; to complete, finalize
                                         and file our FDA submission including our pre-market notification to the FDA for 510(k)
                                         clearance and all other documentation necessary to obtain FDA approval of our insulin
                                         pump. This will include the following: </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">engage
                                         the FDA in a pre-submission conference to ensure that we understand and meet the FDA&rsquo;s
                                         requirements, expectations and standards with regard to approval of our product. At this
                                         meeting, our team, including our FDA regulatory consultant, will receive FDA comments
                                         and guidance regarding our proposed submission during the pre-market notification period
                                         for 510(K) clearance (including any suggested modifications to the device description,
                                         indications for use or summary of supporting data contained in the notification). We
                                         currently expect such conference will be conducted near the end of the third quarter
                                         of 2019. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepare
                                         and ensure that our pre-market notification that will be part of our FDA submission,
                                         demonstrates that our insulin pump is substantially equivalent to an insulin pump previously
                                         cleared by the FDA and legally marketed to the public.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">prepare
                                         our submission to the FDA, to include all of the appropriate results of tests (relating
                                         to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility)
                                         demonstrating safety and efficacy of our insulin pump in satisfaction of the mandates
                                         of the Federal Food, Drug and Cosmetics Act (the &ldquo;FDCA&rdquo;), including requirements
                                         with regard to registration and listing, labeling, medical device reporting and good
                                         manufacturing practices. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
                                         currently expect to make this submission near the end of the last quarter of 2019 or
                                         in the first quarter of 2020.</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Together
                                         with our FDA regulatory consultant, take such actions, if any, as may be required by
                                         the FDA as a condition to granting approval and providing 510(k) clearance for our insulin
                                         pump</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">At
                                         the point that we feel confident of the FDA approval and clearance process relating to
                                         our insulin pump, select a manufacturer of our insulin pump through a competitive bidding
                                         process</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Retain
                                         appropriate sales and marketing personnel to develop, implement and launch a promotional
                                         campaign for our insulin pump substantially focused on our target market</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">As with any medical
device attempting to enter and successfully compete with existing products in an established and competitive marketplace, we will
face significant hurdles to accomplish the above steps to commercialization including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Obtaining
                                         FDA 510(K) clearance to market and sell our insulin pump to the public</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Obtaining
                                         all other FDA approvals with regard to our product required by the FDCA</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Educating
                                         endocrinologists, who typically prescribe pump usage, as to the superior qualities of
                                         our product</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Demonstrating
                                         to general practitioners, who have been historically skeptical of the heightened support
                                         inherent in insulin pumps, of our product&rsquo;s ease of use and convenience</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ensuring
                                         that our final product does in fact meet the needs of almost pumpers.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overcoming
                                         the historic obstacles and reluctance of almost pumpers to using insulin pumps to treat
                                         their diabetes </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 20.25pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 18pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ensuring
                                         that third party payors agree to cover all or a substantial portion of the purchase price
                                         and recurring costs of the use of our insulin pump.&rdquo;</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>The
Company, page 2</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         expand the disclosure in the third paragraph of this section to disclose the regulatory
                                         status of your insulin pump. Also, tell us whether the &ldquo;substantial feedback&rdquo;
                                         mentioned on page 2 has revealed any material disadvantages of your insulin pump.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">To
                                         comply with the Staff&rsquo;s comments, we have added the following language in the &ldquo;Our
                                         Business&rdquo; section of the Registration Statement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Before we can
market our prototype insulin pump to the public, we will need to obtain FDA clearance. Our insulin pump is and will be subject
to extensive and ongoing regulation by the FDA and other federal, state, and local regulatory bodies. FDA regulations govern,
among other things, product design and development, pre-clinical and clinical testing, manufacturing, labeling, post-market adverse
event reporting, post-market surveillance, complaint handling, repair or recall of products, product storage, record keeping,
pre-market clearance or approval, advertising and promotion, and sales and distribution.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Unless an exemption
applies, each medical device, such as our insulin pump, that is intended to be commercially distributed in the United States requires
either prior 510(k) clearance or pre-market approval (&ldquo;PMA&rdquo;) from the FDA. Based on the FDA guidance documents that
we have reviewed and the opinion of our FDA regulatory consultant, we expect to be subject to the shorter and more streamlined
510(k) process, which typically involves less risk of uncertainty and the submission of less supporting documentation, and without
the costly clinical trials associated with PMA. Generally, gaining 510(k) clearance for a product turns on demonstrating that
the subject product is &ldquo;substantially equivalent&rdquo; to a previously cleared 510(k) device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">We are &nbsp;working
&nbsp;closely with our FDA regulatory consultant to complete, finalize and file our FDA submission, including our pre-market notification
to the FDA for 510(k) clearance and all other documentation necessary to obtain FDA approval of our insulin pump. This will involve
three material steps. First, we will engage the FDA in a pre-submission conference to ensure that we understand and meet the FDA&rsquo;s
requirements, expectations and standards with regard to approval of our product. At this meeting, our team, including our FDA
regulatory consultant, will receive FDA comments and guidance regarding our proposed submission during the pre-market notification
period for 510(K) clearance (including any suggested modifications to the device description, indications for use or summary of
supporting data contained in the notification). We currently expect such conference will be conducted near the end of the third
quarter of 2019. Second, we will prepare our pre-market notification to be part of our submission to the FDA, demonstrating that
our insulin pump is substantially equivalent to an insulin pump previously cleared by the FDA and legally marketed to the public.
Third, we will prepare our submission to the FDA, to include all of the appropriate results of tests (relating to, among other
things, user effectiveness, sterility, pump efficiency and shipping compatibility) demonstrating safety and efficacy of the product
in satisfaction of the mandates of the Federal Food, Drug and Cosmetics Act (the &ldquo;Act&rdquo;), including requirements with
regard to registration and listing, labeling, medical device reporting and good manufacturing practices. We currently expect to
make this submission near the end of the fourth&nbsp;quarter of 2019 or in the first quarter of 2020.&rdquo;<B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">We respectfully suggest
that, because of the length of the text, the foregoing is more appropriately inserted in the &ldquo;Our Business&rdquo; section
rather than in the &ldquo;Prospectus Summary&rdquo; section of the Registration Statement, where the Staff asked that the disclosure
be inserted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Rather than revealing
material disadvantages with regard to our pump, the &ldquo;specific feedback&rdquo; (&ldquo;substantial feedback&rdquo; in the
prior version) that we have received has highlighted patients&rsquo; preferred attributes that we have taken into account and
we have refined our prototype accordingly. For example, based on feedback from patients in our target market segment, we have
modified our product to meet several user preferences, such as enhanced compatibility with smart phones, the flexibility for pump
usage for limited periods of time without a controller and the ability to temporarily remove the pump.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>The
Private Placement Transactions, page 2</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 30.55pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Please reconcile the
number of shares purchased for cash in the 2017 placement as disclosed here and on page F-10. Also, if some of the selling shareholders
did not pay cash for the offered securities, please disclose the number of shares exchanged for new shares and when the exchanged
shares were &ldquo;previously canceled&rdquo;; include appropriate disclosure regarding the exchange in your &ldquo;Selling Shareholders&rdquo;
section regarding each selling shareholder who did not pay cash.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">On
April 28, 2017, Manchester Explorer, L.P. (&ldquo;<U>Manchester</U>&rdquo;), purchased 2,900,000 shares of common stock of the
Company, resulting in Manchester owning approximately 83% of the issued and outstanding shares of common stock of the Company.
The purchase price paid by Manchester for such 2,900,000 shares was $375,000. As a condition to, and simultaneously with, the
closing of the 2017 Placement and the Company&rsquo;s acquisition of Quasuras, on July 24, 2017, Manchester cancelled all of such
2,900,000 shares and purchased 4,545,455 shares in the 2017 Placement for $3,000,000. As consideration for Manchester cancelling
the 2,900,000 shares, the Company agreed to repay Manchester the $375,000 purchase price it paid for the 2,900,000 shares. However,
because the Company did not want to use its limited cash resources (the net proceeds received in the 2017 Placement), to buy back
such 2,900,000 shares, Manchester accepted 568,182 restricted shares in the 2017 Placement (with such share being valued at $0.66
per share, the same price as paid by all purchasers in the 2017 Placement) from the Company in lieu of a $375,000 cash payment.
In addition to being disclosed in the Company&rsquo;s fiscal year 2019 and 2018 audited financial statements, this arrangement
was also disclosed to purchasers in the private placement and in the Company&rsquo;s Current Report on Form 8-K filed with the
Commission on July 29, 2017. It is worth noting that the $0.66 per share value of the 568,182 shares accepted by Manchester for
the cancellation of its 2,900,000 shares was significantly greater than the $0.13 per share purchase price Manchester originally
paid for the 2,900,000 shares that it purchased from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">As
requested, the language in the Registration Statement under the heading &ldquo;Prospectus Summary &ndash; The Private Placement
Transactions&rdquo; has been revised so as to reconcile such language with the disclosure on page F-10 of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Except
as disclosed in the first paragraph of this Response 5 with regard to Manchester, all other Selling Shareholders paid cash for
their Shares in one or both of the 2 Private Placements. As a result, except as noted in the immediately preceding sentence, no
other revisions to the &ldquo;Selling Shareholders&rdquo; section have been made in response to the Staff&rsquo;s comments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Corporate
History and Background, page 3</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         provide us your analysis of whether you are an &ldquo;emerging growth company&rdquo; as
                                         defined in Section 2 of the Securities Act.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Based
upon the definition of an &ldquo;emerging growth company&rdquo; (an &ldquo;<U>EGC</U>&rdquo;), in Section 2(a)(19) of the Securities
Act, the Company believes that, because its total annual gross revenues during the most recent fiscal year (March 31, 2019), were
less than $1.07 billion, it has not issued more than $ 1 billion in non-convertible debt in the past three years and is not a
&ldquo;large accelerated filer&rdquo; (as defined in Rule 12b-2 of the Exchange Act), the Company qualifies as an EGC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
reflect the above and certain additional disclosure relating to certain implications under the federal securities laws of being
classified as an EGC, we have checked the EGC box on the Registration Statement cover page, added disclosure to the Prospectus
cover page, in the Prospectus Summary and Risk Factors section of the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Risk
Factors, page 4</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         include appropriate risk factors regarding (1) the conclusions of your CEO and CFO related
                                         to the effectiveness of your controls and procedures and (2) the extent of your board
                                         of directors&rsquo; ability to adopt any recapitalization by effecting a forward or reverse
                                         split of the outstanding shares of your common stock without shareholder approval. We
                                         note your Article IX of exhibit 3.1.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 31.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
accordance with the Staff&rsquo;s above request, we have added the following two Risk Factors to the Registration Statement:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>&ldquo;<I>If
                                         we are unable to effectively implement or maintain a system of internal control over
                                         financial reporting, we may not be able to accurately or timely report our financial
                                         results and our stock price could be adversely affected.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Section&nbsp;404
of the Sarbanes-Oxley Act of 2002 and related regulations require our management to evaluate the effectiveness of our internal
control over financial reporting as of the end of each fiscal year. Based on its evaluations, our management concluded that there
were material weaknesses in our internal control over financial reporting and management concluded that the Company&rsquo;s internal
controls over financial reporting were not effective as of March 31, 2019. Such material weaknesses related to inadequate internal
controls over financial reporting, and the lack of segregation of duties in our financial reporting process. Specifically, management
noted that we do not have a separately designated audit committee or an independent director. Any failure to implement new or
improved controls necessary to remedy the material weaknesses described above, or difficulties encountered in the implementation
or operation of these controls, could harm our operations, decrease the reliability of our financial reporting, and cause us to
fail to meet our financial reporting obligations, which could adversely affect our business and reduce our stock price.&rdquo;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><I>&ldquo;Our
                                         Board of Directors is able to adopt recapitalizations through forward or reverse splits
                                         of our outstanding shares of common stock without shareholder approval.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant
to Article IX of our second amended and restated articles of incorporation, our board of directors has the power, without obtaining
shareholder approval, to effectuate recapitalizations of the Company through forward or reverse splits of our outstanding common
stock. As a result of such provision, our board of directors can implement recapitalizations of the Company by effectuating a
forward or reverse stock split of our outstanding common stock, which would increase or decrease each of our shareholder&rsquo;s
number of shares owned, and our shareholders will have no right to approve or disapprove any such action even if such actions
have a material adverse effect on them.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your disclosure on page 23 regarding your Board of Directors being elected annually.
                                         Please show us how you comply with Regulation 14A or 14C, as appropriate, in connection
                                         with shareholder action. Also clarify whether shareholders have the ability to vote on
                                         the directors appointed under the agreement mentioned on page 34. Include any appropriate
                                         risk factors.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
the July 24, 2017 agreement pursuant to which the Company acquired Quasuras, the Company agreed that for a period of 5 years following
such date the Company&rsquo;s board of directors would consist of no less than 2 and no more than 5 directors. Of such directors,
Manchester would have the right to appoint two directors, one of whom would be Mr. Frank, and Mr. DiPerna, in addition to being
chairman, would have the right to appoint two additional directors. On January 26, 2019, Liam Burns was appointed a director,
which appointment constituted one of the two additional directors that Mr. DiPerna has the right to appoint. As a result, other
than such above appointees, no new directors have been elected or appointed, either at an annual meeting of shareholders or by
written consent of the Company&rsquo;s shareholders, since that time and, therefore, compliance with Regulation 14A or 14C was
not implicated. Taking into account the Staff&rsquo;s Comment 8 and the above, we have amended the Section of the Registration
Statement entitled &ldquo;Description of Common Stock&mdash;Common Stock&rdquo; accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Additionally,
to more specifically disclose the above risk, as requested by the Staff, we have revised the relevant risk factor contained in
the &ldquo;Risk Factor&rdquo; section of the Registration Statement to read as follows:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B><I>&ldquo;If
                                         the beneficial ownership of our stock continues to be highly concentrated, it may prevent
                                         you and other shareholders from influencing significant corporate decisions; right of
                                         certain parties to appoint directors.</I></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">As of June 30, 2019,
our executive officers, directors and certain persons who may be deemed their affiliates beneficially owned substantially in excess
of 50.1% of our issued and outstanding common stock. As a result, such persons may exercise substantial influence over the outcome
of corporate actions requiring shareholder approval including, without limitation, the election of directors, certain mergers,
consolidations and sales of all or substantially all of our assets or any other significant corporate transactions. Such persons
may also vote against a change of control, even if such a change of control would benefit our other shareholders. In addition,
pursuant to the July 24, 2017 agreement pursuant to which we acquired Quasuras, until July 24, 2022, our board of directors will
consist of no less than 2 and no more than 5 directors, of which Mr. DiPerna, in addition to being our chairman, has the right
to appoint 2 additional directors and Manchester has the right to appoint 2 directors, of which Mr. Frank constitutes 1 such director.
As a result of such agreement, until July 24, 2022, other shareholders will not have the ability to elect any directors either
at the annual meeting or by written consent, even if such other shareholders believe that our board of directors is taking actions
to which the shareholders object. See &ldquo;Stock Ownership by Principal Shareholders and Management&rdquo; below.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Any
failure to attract and retain skilled directors, executives, employees and consultants, page 7</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your disclosure on page 33 that Mr. DiPerna is the manager of one entity and the
                                         chief executive officer of another entity. Please add a risk factor to highlight, if
                                         appropriate, the amount of time Mr. DiPerna may work on your business and any conflicts.
                                         Also, please tell us why the disclosure on page 33 does not address the activity mentioned
                                         at the end of schedule 1.1 of exhibit 10.4.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">For
the reasons set forth below,&nbsp;the Company does not believe that Mr. DiPerna&rsquo;s affiliations with the entities reflected
on Schedule 1.1 to his employment contract involve any material conflict relative to his duties to the Company and respectfully
submits that a risk factor in that respect is not necessary. The Company&rsquo;s position is based on the business activities
in which these companies are engaged, their current level of activity and the time that Mr. DiPerna devotes to the affairs of
such businesses. With regard to National Cardiac, Inc., a company developing a low cost external heart monitor, Mr. DiPerna has
indicated that he is no longer the chief executive officer and is now just a board member with just a minority (5%) stake and
devotes less than one hour per month to the affairs of this company, which is currently not generating any revenue. According
to Mr. DiPerna, Fuel Source Partners, LLC is primarily Mr. DiPerna&rsquo;s personal vehicle through which he had operated his
consulting activities and that the activities of this company are now nearly dormant, such that Mr. DiPerna devotes less than
one hour per month to this company. With regard to Patient Focused Innovation Partners LLC (&ldquo;<U>PFIP</U>&rdquo;), which
is involved with weight-loss treatment, Mr. DiPerna indicated that he is one of three owner members of this company, which currently
has no operations other than managing patent applications. Mr. DiPerna also indicated that he expects that the affairs of this
company will be completely wound down by the end of 2019, and he is currently devoting less than one hour per month to PFIP activities.
&nbsp;Based upon the above, we respectively inform the Staff that we believe that no additional risk factor disclosure is necessary
with regard to the Staff comment 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
the above, the Company has added the following two sentences to the end of Mr. DiPerna&rsquo;s biographical information in the
&ldquo;Management&rdquo; section of the Registration Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;In
addition to FCP and Cardiac, Mr. DiPerna is one of 3 owners of a company that currently manages patent applications with regard
to a gastric delivery system. Mr. DiPerna has informed us that he devotes less than 3 hours per month in the aggregate to these
activities which he expects to further decrease over time.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>We
will need to outsource and rely on third parties, page 7</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         expand the appropriate section to disclose the material termination provisions of your
                                         agreements mentioned in the third sentence of the second paragraph of this risk factor.
                                         Also, provide us your analysis of whether you must file any of the agreements as exhibits
                                         to your registration statement.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s request, we have revised the following Risk Factor in the Registration Statement to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&ldquo;We
do not have internal research and development personnel, making us dependent on consulting relationships and strategic alliances
with industry partners.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">We
consider research and development to be an important part of the process of designing, developing, obtaining regulatory required
approvals and the eventual commercialization of our insulin pump. For the quarter ending June 30, 2019, our research and development
expenditures increased approximately 518% to $703,783 from $135,789 during the same quarter in 2018. For our fiscal year ended
March 31, 2019, research and development expenditures increased by 466% to $1,882,345 as compared to $332,642 for fiscal year
2018. Such increases in research and development expenditure are attributable to effort and expenses incurred in designing and
developing our innovative insulin pump. We expect to continue to incur substantial costs related to research and development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">We
currently have no research and development personnel, and rely and expect for the foreseeable future to continue to rely, on third
party consultants to perform such functions for us. As a result, we are and expect to continue for the foreseeable future to be
dependent on such third parties. Generally, our contracts with such third parties, are terminable for any reason by us or such
third parties on 2 weeks to 30 day notice (with one exception providing for 90 days&rsquo; notice) and provide for no severance
or termination benefits to such third parties. As a result, such third parties may be able to terminate their contractual relationships
with us quickly and with little, if any, notice. Although we believe there is a relatively large and readily accessible network
of third parties that we can draw from to replace any of our then third party consultants, no assurances can be given that we
would be able to quickly and seamlessly find and hire suitable replacements. Any material interruption or delay in our research
and development activities performed by our third party consultants could impair our ability to meet any deadlines and materially
impair our then product design and development, regulatory approval and/or commercialization activities which could have a material
adverse effect on our business, financial condition and stock price. In addition, if we do not appropriately manage our relationships
with such third parties, we may not be able to efficiently manage the development, testing, regulatory approval and eventual commercialization
of our insulin pump, which also could have a material and adverse effect on our business, financial condition and stock price.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Please
note that because of the short term and &ldquo;project by project&rdquo; nature of these standard consulting contracts and the
fact that the third party consultants and contractors retained thereunder are not &ldquo;significant employees&rdquo; (as defined
in Regulation S-K Item 401(c)), we do not believe that these standard consulting contracts need to be filed as exhibits to the
Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Selling
Shareholders, page 16</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your disclosure indicating that footnotes would contain any exceptions to your statements
                                         in the last sentence of the first paragraph. Please ensure that the footnotes that you
                                         mention describe the exceptions.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">With
regard to the last sentence of the first paragraph of the Selling Shareholders section of the Registration Statement, the only
exception relates to Mr. DiPerna&rsquo;s positions with the Company during the last three years, which we confirm is disclosed
in footnote 11 to the Selling Shareholders Table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Our
Solution, page 27</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         disclose the basis, to the extent material, for your belief that your &ldquo;proposed
                                         insulin pump will be the simplest and least expensive product on the market and the easiest
                                         for physicians to prescribe for diabetes patients&rdquo; in view of the status of your
                                         product mentioned in the fourth paragraph on page 27. Also, if claims regarding safety
                                         can be made only after the FDA has not cleared a product for sale, please tell us why
                                         you believe it is appropriate to make claims regarding safety like you do on page 27.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
response to the Staff&rsquo;s comments, we have revised the &ldquo;Our Business&rdquo; section of the Registration Statement to
delete the following two sentences on page 27:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">We
believe that, owing to our new proprietary technology, our proposed insulin pump will be the simplest and least expensive product
on the market and the easiest for physicians to prescribe for diabetes patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">We
believe such prototype will need to be modified to provide the safety features required to meet today&rsquo;s standards and manufacturing
considerations and to restrain costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Government
Regulation, page 28</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 9pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 27pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>13.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your disclosure regarding your intended consumers in the last sentence on page 27.
                                         Please tell us why this section does not address the regulatory process of relevant foreign
                                         authorities.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
United States has by far the highest incidence of people with diabetes using pumping technology, such that the Company&rsquo;s
immediate focus in terms of marketing its prototype product is exclusively in the United States.&nbsp; The Company has explored
some foreign opportunities and,&nbsp;with regard to surveying markets in&nbsp;the European Union, has retained a business development
consultant&nbsp;to conduct a cursory review of the process of gaining CE approval and to consider the protocols for regulatory
approval in various countries. However, these overtures are relatively premature and far from being implemented. The Company has
no current concrete plans to market its product in Europe in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
response to the Staff&rsquo;s comment, the phrase &ldquo;and around the world&rdquo; in the &ldquo;Our Business&rdquo; section
on page 27 of the Registration Statement (page 31 of Amendment No. 1) has been deleted.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>14.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your disclosure that you anticipate that your proposed product will require the
                                         PMA approval process. Please more fully disclose the nature of that process; include,
                                         as applicable, the investigational device exemption process, and, if needed, whether
                                         you have received the exemption. Also disclose the duration of the PMA process, and clarify
                                         the nature of the &ldquo;more rigorous examination&rdquo; that you mention in the first
                                         sentence on page 29.</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Our
                                         original expectation, reflected in the &ldquo;Our Business&rdquo; section on page 29
                                         of the Registration Statement, that our product would be subject to PMA, was based on
                                         the fact that we were once considering constructing our product in such a way that insulin
                                         was to be inserted in our pump&rsquo;s cartridge. Since we are no longer considering
                                         constructing our pump in that manner, that language is no longer appropriate. Consequently,
                                         in response to the staff&rsquo;s comment, the &ldquo;Our Business&rdquo; section of the
                                         Registration Statement has been revised to delete the following sentence:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">We
                                         anticipate that our proposed product will require the more costly, lengthy and uncertain
                                         PMA approval normal process.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         response to the Staff&rsquo;s comment, the &ldquo;Our Business&rdquo; section of the
                                         Registration Statement has been further revised to include the following:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;Before
                                         we can market our prototype insulin pump to the public, we will need to obtain FDA clearance.
                                         Our insulin pump is and will be subject to extensive and ongoing regulation by the FDA
                                         and other federal, state, and local regulatory bodies. FDA regulations govern, among
                                         other things, product design and development, pre-clinical and clinical testing, manufacturing,
                                         labeling, post-market adverse event reporting, post-market surveillance, complaint handling,
                                         repair or recall of products, product storage, record keeping, pre-market clearance or
                                         approval, advertising and promotion, and sales and distribution.&nbsp;&nbsp;&nbsp;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Unless
                                         an exemption applies, each medical device, such as our insulin pump, that is intended
                                         to be commercially distributed in the United States requires either prior 510(k) clearance
                                         or pre-market approval (&ldquo;PMA&rdquo;) from the FDA. Based on the FDA guidance documents
                                         that we have reviewed and the opinion of our FDA regulatory consultant, we expect to
                                         be subject to the shorter and more streamlined 510(k) process, which typically involves
                                         less risk of uncertainty and the submission of less supporting documentation, and without
                                         the costly clinical trials associated with PMA. Generally, gaining 510(k) clearance for
                                         a product turns on demonstrating that the subject product is &ldquo;substantially equivalent&rdquo;
                                         to a previously cleared 510(k) device.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The
                                         FDA&rsquo;s 510(k) clearance pathway generally takes from three to twelve months from
                                         the date the application is completed, but, if additional testing, verifications or other
                                         procedures (or even clinical trials in care instances) are required, can take significantly
                                         longer (as compared to PMA which can extend from one to three years, or longer in certain
                                         instances). After a medical device receives 510(k) clearance, any modification that could
                                         significantly affect its safety or effectiveness, or that would constitute a significant
                                         change in its intended use, requires a new 510(k) clearance or, depending on the modification,
                                         could require a PMA application. The FDA requires each manufacturer to make this determination
                                         initially, but the FDA can review any such decision and can disagree with a manufacturer&rsquo;s
                                         determination. If the FDA disagrees with a manufacturer&rsquo;s determination regarding
                                         whether a new premarket submission is required for the modification of an existing device,
                                         the FDA can, at its discretion, require the manufacturer to cease marketing and/or recall
                                         the modified device until 510(k) clearance is obtained. Failure to comply with applicable
                                         regulatory requirements can result in enforcement actions by the FDA and other regulatory
                                         agencies, which may include any of the following sanctions: untitled letters or warning
                                         letters, fines, injunctions, consent decrees, civil or criminal penalties, recall or
                                         seizure of our current or future products, operating restrictions, partial suspension
                                         or total shutdown of production, refusal of or delay in granting 510(k) clearance of
                                         new products or modified products or rescinding previously granted 510(k) clearances.
                                         Any of these sanctions could result in higher than anticipated costs and have a material
                                         adverse effect on our reputation, business and financial condition. See &ldquo;Risk Factor
                                         &ndash; Government Regulation,&rdquo; above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -30.55pt"><FONT STYLE="font-size: 10pt">The
FDA can delay, limit or deny clearance or approval of our proposed pump device for many reasons, including:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">our
                                         inability to demonstrate that our product is safe and effective for its intended users&#894;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">our
                                         inability to demonstrate that our product is the &ldquo;substantial equivalent&rdquo;
                                         of a previously cleared device;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">the
                                         data from our user studies may be insufficient to support clearance or approval&#894;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">failure
                                         of the manufacturing process or facilities we use to meet applicable requirements.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         addition, the FDA may change its clearance and approval policies, adopt additional regulations
                                         or revise existing regulations, or take other actions which may prevent or delay approval
                                         or clearance of our pump.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By
                                         the reference to &ldquo;more rigorous examination&rdquo; on page 29 (page 33 of Amendment
                                         No. 1), we mean that, although we anticipate that we will be subject to the 510(k) process
                                         and not to the lengthier review period, increased documentation requirements and clinical
                                         trials involved in PMA, we may nonetheless be subject to additional testing, further
                                         verification and any other procedures that may be required at the direction of the FDA.&rdquo;</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 5.45pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Operating
Expenses, page 30</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>15.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         clarify the nature of the consulting services mentioned in the second sentence of this
                                         section. Also, clarify what you mean by the phrase &ldquo;increasing outside expenses.&rdquo;</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">For
                                         the cost and flexibility reasons mentioned in the response to paragraph 10 above, we
                                         rely on outside expert consultants to conduct our regulatory submission process, laboratory
                                         testing procedures, and quality control mechanisms. We also will rely heavily on outside
                                         contractors for manufacturing our products.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         response to the staff&rsquo;s request, we modified the &ldquo;Management&rsquo;s Discussion
                                         and Analysis of Financial Condition and Results of Operations&rdquo; section of the Registration
                                         Statement to include the following:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 30.55pt; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;By increasing outside
expenses, we mean that, as we continue to implement product design enhancements and as we further progress along the path to FDA
approval,&nbsp;these expenses will escalate.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Management,
page 33</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>16.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>If
                                         you elect to highlight achievements related to the companies that you mention, please
                                         ensure that your disclosure is balanced. For example, did the companies incur material
                                         losses?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9;To
conform to the Staff&rsquo;s request, we have revised Mr. DiPerna&rsquo;s biographical information &#9;set forth in the &ldquo;Management&rdquo;
section of the Registration Statement to delete the &ldquo;highlight &#9;achievements&rdquo; related to the companies discussed
therein, so as to read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Paul
DiPerna</B>&nbsp;is and has been since our July 24, 2017 acquisition of Quasuras, our chairman, chief executive officer, chief
financial officer, secretary and treasurer. Mr. DiPerna began his career in approximately 1980 as a mechanical design engineer
in the automated test equipment industry before moving in approximately 1989 to a start-up in the blood separation sciences industry.
This company was eventually acquired in approximately 1991 by Baxter Healthcare (&ldquo;Baxter&rdquo;). Following such acquisition,
Mr. DiPerna became employed by Baxter and held various positions during his approximate 12 years at Baxter. While at Baxter, Mr.
DiPerna worked on numerous projects and initiatives including leading a team of approximately 50 engineers in developing equipment
in the blood separation sciences industry. In approximately 1996, Mr. DiPerna was promoted to General Manager of Baxter&rsquo;s
business development group to identify targets for Baxter&rsquo;s expansion opportunities in the medical device industry. While
holding such position, Mr. DiPerna led a team researching custom orthopedics, digital dentistry and rapid prototyping. In such
role, one of Mr. DiPerna&rsquo;s assignments was identifying synergistic opportunities in the diabetes industry.&nbsp;As a result,
Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire three
insulin pump manufacturers. In 2003, Mr. DiPerna left Baxter and founded what subsequently became Tandem Diabetes Care, Inc. (&ldquo;Tandem&rdquo;).
While at Tandem, Mr. DiPerna held various positions, including as director, chief executive officer and chief technology officer
and was primarily responsible for the design concept and development of Tandem&rsquo;s initial insulin pump, which subsequently
was commercialized by Tandem. Tandem is a medical device company that designs, develops and commercializes products for people
with insulin dependent diabetes. In 2011,<B>&nbsp;</B>Mr. DiPerna resigned from his executive officer position and board seat
at Tandem but continued to assist the company through 2013. In approximately January, 2012, Mr. DiPerna was the co-inventor with
regard to a private company with property rights in a medical device used for blood borne infection control called the &ldquo;Curos
Cap.&rdquo; Curos Cap was acquired by 3M Corporation in 2015. Thereafter, Mr. DiPerna founded a company, Fuel Source Partners,
LLC (&ldquo;FSP&rdquo;), where he is the manager of, to incubate early stage medical device products and accumulate technical
talent. One of such proposed products was spun-out to Quasuras in March 2015, which we acquired in July 2017. Mr. DiPerna owns
a variety of, patents and patents pending and is a member of the American Diabetes Association. Mr. DiPerna received a Masters
in Engineering Management from Northeastern University and a BS in Mechanical Engineering from the University of Lowell.&nbsp;In
January 2017, Mr. DiPerna joined National Cardiac Incorporated (&ldquo;Cardiac&rdquo;) as the chief executive officer and a board
member to leverage Cardiac&rsquo;s technology in the cardiac monitoring space. In addition to FSP and Cardiac, Mr. DiPerna is
one of 3 owners of Patient Focused Innovation Partners (&ldquo;PFIP&rdquo;), a company that manages patent applications with regard
to a weight loss product. Mr. DiPerna has informed us that he devotes less than 3 hours per month in the aggregate to his activities
with FSP, Cardiac and PFIP, which he expects to further decrease over time. We believe that Mr. DiPerna is qualified to serve
as the chairman of our board of directors due to his extensive knowledge and experience in the medical device industry generally,
and, in particular, with regard to insulin pumps and the diabetes industry as well as his management and leadership experience
from holding director and senior executive positions in other public and private companies and leading project development teams
of medical device companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>17.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         provide the disclosure required by Item 401(e)(1) of Regulation S-K regarding the specific
                                         experience, qualifications, attributes, or skills that led to the conclusion that Messrs.
                                         DiPerna, Burns and Frank should serve as directors.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s request, at the end of the biographical information appearing in the &ldquo;Management&rdquo; section
of the Registration Statement for each Messrs. DiPerna, Frank and Burns, the following additional disclosure related to Item 401(e)(1)
of Regulations S-K has been added (as applicable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We
believe that Mr. DiPerna is qualified to serve as the Chairman of our Board of Directors due to his extensive knowledge and experience
in the medical device industry generally and in particular with regard to insulin pumps and the diabetes industry as well as his
management experience from holding director and senior executive positions and leading early project development teams.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We
believe that Mr. Frank is qualified to serve as member of our board of directors due to his extensive prior experience conducting
financial analysis of public companies including development stage companies including of their management teams, products including
products being developed and the potential markets for such products and factors that could effect the likelihood and timing of
success and market penetration as well as his capital raising activities. We believe this not only provides us with valuable insights
into the financial markets and how potential investors and markets may analyze us for capital raising and other related purposes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We
believe that Mr. Burns is qualified to serve as a member of our board of directors due to his extensive experience and background
in developing and launching new medical technologies, commercial strategy, marketing and branding as well as his experience in
metabolic health.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 4.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Involvement
in Legal Proceedings, page 34</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>18.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note the reference to the &ldquo;disclosure with regard to Mr. Burns;&rdquo; however, the
                                         disclosure appears to be missing. Please advise or revise.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The
Staff&rsquo;s comment is addressed by the insertion of the following in the biography of Liam Burns in the &ldquo;Management&rdquo;
section of the Registration Statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;From
January 2014 to March 2018, he was the Vice President, Global Sales and Marketing for Dextera Surgical Inc., which marketed the
world&rsquo;s smallest surgical stapler. Dexteria Surgical Inc. filed for bankruptcy protection on December 11, 2017 and was subsequently
sold to B. Braun Aesculap in 2018. .From January 2013 to September 2016, Mr. Burns was the managing member and majority interest
holder in Bensi Flemington LLC., which operated a restaurant in Flemington, New Jersey. Bensi Flemington LLC filed for bankruptcy
protection on August 11, 2015.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>The
DiPerna Employment Agreement and Related Agreements, page 35</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>19.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         disclose the post-termination compensation provision mentioned in section 5(c) of exhibit
                                         10.4 and the change of control compensation mentioned in section 6 of that exhibit. Also,
                                         file as exhibits to your registration statement the agreements mentioned in the last
                                         sentence of this section.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s request, we have added the below disclosure to the last sentence of the first paragraph of the section
in the Registration Statement titled &ldquo;Management &ndash; The DiPerna Employment and Related Agreements&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;In
addition pursuant to our employment agreement with Mr. DiPerna, in the event that we terminate Mr. DiPerna&rsquo;s employment
without cause or he resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000. In the event that we terminate Mr.
DiPerna&rsquo;s employment for cause, we are not obligated to make any severance payment and Mr. DiPerna will receive only his
base compensation through the last day of his employment. In the event of Mr. DiPerna&rsquo;s death or disability, he will receive
his base compensation through the last day of his employment and will remain eligible for all applicable benefits relative to
death or disability pursuant to any plans that we have in place at such time. In the event of a &ldquo;change in control&rdquo;
(as defined in the employment agreement), Mr. DiPerna will be paid a lump sum of $100,000 within sixty days of the time at which
such change of control takes place.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Although
the Registration Statement stated that the Intellectual Property Assignment Agreement and Technology Royalty Agreement were filed
as Exhibits to Form 8-K on July 29, 2017 and were incorporated by reference therein, we have added these two agreements as Exhibits
10.5 and 10.6 to Amendment No. 1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Composition
of the Board, page 35</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>20.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         describe the effect of section 3.03 of exhibit 3.2 to your registration statement.<U>
                                         Executive Compensation, page 37</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
response to the Staff&rsquo;s comment, we note the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Section
3.03 of the Company By-Laws provides:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Classification
of Directors. In lieu of electing the entire number of directors annually, the Board of Directors may provide that the directors
be divided into either two or three classes, each class to be as nearly equal in number as possible, the term of office of the
directors of the first class to expire at the first annual meeting of shareholders after their election, that of the second class
to expire at the second annual meeting after their election, and that of the third class, if any, to expire at the third annual
meeting after their election. At each annual meeting after such classification, the number of directors equal to the number of
the class whose term expires at the time of such meeting shall be elected to hold office until the second succeeding annual meeting,
if there be two classes, or until the third succeeding annual meeting, if there be three classes.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify; text-indent: 40.8pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">However,
as discussed&nbsp;in greater detail in Response 8 above, pursuant to the 2017 agreement pursuant to which we acquired Quasuras,
until July 24, 2022, the Company&rsquo;s&nbsp;board of directors consists of no more than five (5) and no less than two (2) directors
of which (i) MMC has the right to appoint two (2) such directors, one of whom is Mr. Frank, and (ii) Mr. DiPerna has&nbsp;the
right, in addition to being Chairman, to appoint 2 additional directors. As a result, Section 3.03 of the Company&rsquo;s by-laws
will not be implicated at least until July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>21.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         reconcile your disclosure in the table on page 38 about the salary of $30,000 and all
                                         other compensation of $105,000 for the fiscal year ended March 31, 2018 with your disclosure
                                         in footnote (1) on page 38 that Mr. Diperna was named CEO on July 24, 2017 at an annual
                                         salary base of $180,000. Also, clarify how the option grant mentioned in the first paragraph
                                         on page 39 is reflected in the first table on page 38, and note the disclosure required
                                         by the Instructions to Regulation S-K Item 402(c)(2)(v) and (vi) or Item 402(n)(2)(v)
                                         and (n)(2)(vi), as appropriate.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
response to the Staff&rsquo;s comment, we have revised the &ldquo;Executive Compensation &ndash; Summary Compensation Table (Executive
Officers and Directors)&rdquo; to read as follows:<B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SUMMARY
COMPENSATION TABLE (Executive Officers and Directors)</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0">Name and <BR> Principal<BR> Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year<BR> Ended<BR> March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock<BR> Awards<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Awards<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All<BR> Other<BR> Compensation<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="width: 10%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Paul DiPerna,&#9;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">2019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">192,510</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">42,761</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">-0-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">235,271</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CEO, CFO,&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">135,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Secretary,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Treasurer and</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Director (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Morgan Frank, Director&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD STYLE="text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Liam Burns,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">Director (2)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,249</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr.
                                         DiPerna was named Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer
                                         and a Director of the Company on July 24, 2017 at an annual salary base of $180,000,
                                         which was increased to $300,000 in August 2018. Pursuant to his employment agreement
                                         then in effect,&nbsp;for the fiscal year ending March 31, 2018, Mr. DiPerna had received
                                         $105,000 as a consultant and $30,000 in salary which represented his base compensation
                                         through the end of that reporting period. &nbsp;During this period, the Company did not
                                         have employees, only consultants.&nbsp; The Company implemented a payroll provider through
                                         ADP in February 2018&nbsp;and certain key consultants, including Mr. DiPerna, were added
                                         to the Company&rsquo;s payroll as employees. On August 15<SUP>th</SUP>, September 15<SUP>th</SUP>&nbsp;and
                                         October 15<SUP>th</SUP>, 2018, the Company granted 54,039 options to Mr. DiPerna in lieu
                                         of salary. The options expire on August 14<SUP>th</SUP>, September 14<SUP>th</SUP>&nbsp;and
                                         October 14<SUP>th</SUP>, 2028 and vest immediately. The fair value of these options was
                                         determined to be $24,840. On November 15<SUP>th</SUP>&nbsp;and December 15<SUP>th</SUP>&nbsp;2018,
                                         the Company granted 10,648 options to Mr. DiPerna in lieu of salary. The options expire
                                         on November 14<SUP>th</SUP>, and December 14<SUP>th</SUP>, 2028 and vest immediately.
                                         The fair value of these options was determined to be $17,921. The following assumptions
                                         were used in the fair value method calculation: volatility: 71%&nbsp;&ndash; 112%; risk
                                         free rate of return: 2.73% &ndash; 3.01%; and expected term: 5 years.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Mr.
                                         Burns entered into a services contract to serve on our Board of Directors for an annual
                                         retainer of $10,000 paid quarterly together with a grant of 90,000 non-qualified stock
                                         options under our EIP with a three year vesting period and an exercise price of $2.25
                                         per share. On January 16, 2019, the Company granted 90,000 options to Mr. Burns, these
                                         options will be fully vested three years from the date granted (the vesting schedule
                                         provides that 33% of such options will vest on the first anniversary of the grant date).
                                         The 90,000 options will expire on January 15, 2029. The fair value of the options 90,000
                                         shares was determined to be $163,620 and $24,478 had accrued as of June 30, 2019. On
                                         April 15<SUP>th</SUP> and May 15<SUP>th</SUP> 2019, the Company granted 8,907 options
                                         to Liam Burns, these options will be fully vested on the grant date. The 8,907 options
                                         will expire on April 14 and May 14, 2029. The fair value of the 8,907 options was determined
                                         to be $15,000. The following assumptions were used in the fair value method calculation:
                                         volatility: 97.49% - 104%; risk free rate of return: 2.15% - 2.54%; and expected term:
                                         5 - 5.88 years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Related
Party Transactions, page 40</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>22.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>We
                                         note your reference to $120,000 in the first paragraph. Please revise given the threshold
                                         in Regulation S-K Item 404(d)(1). Also, provide disclosure that addresses the entire
                                         time period mentioned in Instruction 1 to Item 404.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s request, we have revised the disclosure set forth in the section of the Registration Statement titled
&ldquo;Related Party Transactions&rdquo;. Such section now reads as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;A
&ldquo;Related Party Transaction&rdquo; means a transaction (including any series of related transactions or a material amendment
or modification to an existing Related Party Transaction) directly or indirectly involving any Related Party that would need to
be disclosed under Item 404(a) of Regulation S-K. Generally, under Item 404(a) of Regulation S-K, we are required to disclose
any transaction occurring since the beginning of the last two fiscal years preceding our last fiscal year, or any currently proposed
transaction, involving us or our subsidiary where the amount involved exceeds the lesser of (i) $120,000 or (ii) one percent of
the average of the Company&rsquo;s total assets at year-end for the last two completed fiscal years, and in which any Related
Party had or will have a direct or indirect material interest. A &ldquo;Related Party&rdquo; means any of the following: (i) any
of our directors of the Company or Director Nominees; (ii) any of our executive officers; (iii) a person known by us to be the
beneficial owner of more than 5% of our common stock or (iv) an immediate family member of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt 1in; text-align: justify"><FONT STYLE="font-size: 10pt">Except
as provided elsewhere in this prospectus with regard to Mr. DiPerna, no director, executive officer or affiliate of ours or owner
of record or beneficially of more than five (5%) percent of our common stock is a party to a Related Party Transaction with us.
See &ldquo;Management &ndash; The DiPerna Employment and Related Agreements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Consolidated
Statements of Stockholders&rsquo; Equity, page F-4</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>23.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         revise the penultimate caption of the table to correctly indicate that the net loss is
                                         for the fiscal year ended March 31, 2019, rather than for the quarter ended March 31,
                                         2019.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">As
requested by the Staff, such revision has been made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Note
1 - Organization and Summary of Significant Accounting Policies</U> <U>Earnings Per Share (&ldquo;EPS&rdquo;), page F-9</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>24.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Revise
                                         this note and your Consolidated Statement of Operations on page F-3 to present your earnings
                                         per share to the nearest cent, so as not to imply more precision than exists.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
requested by the Staff, such revisions have been made.</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>25.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Revise
                                         to disclose the securities that could potentially dilute basic EPS in the future that
                                         were not included in the computation of diluted EPS because to do so would have been
                                         anti-dilutive for the periods presented. Refer to ASC 260-10-50-1(c).</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s request, we have added the following on page F-9 to the section of the Financials entitled the &ldquo;Earnings
Per Share (&ldquo;EPS&rdquo;)&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Basic earnings
per share are computed by dividing earnings available to common stockholders by the weighted average number of outstanding common
shares during the period. Diluted earnings per share are computed by dividing net income by the weighted average number of shares
outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding
if the potentially dilutive securities had been issued. During the fiscal years ended March 31, 2019 and 2018 we incurred losses.
Therefore, the effects of any common stock equivalent were anti-dilutive during those periods.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Note
5 - Stockholders&rsquo; Equity</U> <U>Stock Options, page F-11</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>26.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         revise to disclose the method used to estimate the fair value of the equity instruments
                                         granted during the period to both employees and consultants, as well as the underlying
                                         basis for the assumptions used. Refer to ASC 718-10-50-2(f) and 505-50-50-1. In addition,
                                         as applicable, revise to provide the disclosures required by ASC 718-10-50- 2(c) through
                                         (e).</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">In
                                         response to the Staff&rsquo;s request, we have added the following on page F-13 at the
                                         end of the section of the Financials entitled &ldquo;Stock Options&rdquo;:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&ldquo;The
                                         relative fair value of each of the granted options set forth above has been calculated
                                         using the Black&ndash;Scholes&ndash;Merton pricing model, which includes simplified method
                                         to establish fair term of options as well as average volatility of three comparable organizations.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>27.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>You
                                         disclose on page F-12 that options issued to consultants were valued at $682,240 and
                                         was accrued monthly in research and development expenses for the year ended March 31,
                                         2019. However, we note from your statement of cash flows that total stock-based compensation
                                         expense for fiscal year 2019 was $532,108. Please revise to clarify this discrepancy
                                         and to disclose the method used for measuring compensation cost from share- based payment
                                         arrangements.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In
Response to the Staff&rsquo;s request, we have added the following on page F-13 to the section of the Financials entitled &ldquo;Stock
Options&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-size: 10pt">During
the fiscal year ended March 31, 2019, the Company granted options to purchase 1,529,208 shares of common stock to certain employees
and consultants. The fair value of the options granted was $1,021,733, and the Company has been recording stock-based compensation
expense for each grant over the respective vesting periods. For the year ended March 31, 2019, the Company recorded stock-based
compensation expense of $532,108, which is less than the total fair value. This difference of $489,625 represents stock-based
compensation expense that will be recognized subsequent to March 31, 2019, so long as the option grants remain outstanding and
vesting continues. The table below provides a reconciliation of total fair value of the options granted and related expense recognized
by the Company during fiscal 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt; margin-top: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid; padding-left: 0">Grantees</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR>
    Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; padding-left: 0">Vesting <BR>
    Periods</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Fair <BR>
    Value of<BR>
    Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019 Stock-Based <BR>
    Compensation <BR>
    Expense</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Unrecognized <BR>
    expense at <BR>
    March 31, 2019</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="width: 23%; padding-left: 0">Consultants</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 8%; text-align: right">1,280,000</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 22%; padding-left: 0">July 25, 2018 to July 24, 2019</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; text-align: right">682,240</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; text-align: right">466,197</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 3%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">$</TD><TD NOWRAP STYLE="width: 8%; text-align: right">216,043</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0">Consultants</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">185,221</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0">January&nbsp; 16, 2019 to January 15, 2022</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">336,732</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">23,150</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">313,582</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,204)">
    <TD NOWRAP STYLE="text-align: left; padding-left: 0">Chief Executive Officer</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">64,687</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0">*</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">42,761</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">42,761</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&mdash;</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0">Total</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1,529,908</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">1,021,733</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">532,108</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">489,625</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-size: 10pt">* Options were fully vested as of the grant
date, as disclosed above.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>



<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 12pt"><FONT STYLE="font-size: 10pt"><IMG SRC="modularcorresp001.jpg" ALT="(LOGO)">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 7pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Signatures,
page 48</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 5.45pt; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 30.55pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>28.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Please
                                         clarify below the second paragraph of text that Form S-1 requires on the Signatures page
                                         who signed your document in the capacity of principal accounting officer or controller.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To
comply with the Staff&rsquo;s comment, its requested clarification has been made on the signature page to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Please
contact either me or our outside counsel copied hereon, Lawrence Nusbaum and Howard Mulligan of Gusrae Kaplan Nusbaum PLLC, at
212-269-1400, with any questions that you may have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company hereby respectfully submits this letter as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 60%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 40%; text-align: left; padding: 0; text-indent: 0">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; padding: 0; text-indent: 0">/s/ Paul DiPerna</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; text-indent: 0; padding: 0">Paul DiPerna</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; padding: 0; text-indent: 0">Chairman, Chief Executive Officer, <BR>
Chief Financial Officer, Secretary and Treasurer</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0 0 0 0.5in; text-indent: 0; width: 10%">CC:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 90%">Lawrence G. Nusbaum, Esq.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Howard F. Mulligan, Esq.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; border-top: Black 1pt solid; text-align: center; color: #2F5496"><FONT STYLE="font-size: 10pt"><I>800
West Valley Parkway, Suite 203, Escondido, CA 92025 - 760.392.1343 - modular-medical.com</I></FONT></P>


    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>modularcorresp001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modularcorresp001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ /0"! P$1  (1 0,1 ?_$ *0   (# 0$!
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?A]=2O"RIP;KKC0NZ\Q1<M0Z@Q.FG(WX&J8E+UM7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
